A new study suggests that a single pill containing three low-dose blood pressure medications may help prevent another stroke in people who have already had a brain bleed. The research, presented as an abstract at a medical conference, focused on patients with a history of intracerebral hemorrhage (ICH), a type of stroke caused by bleeding in the brain. High blood pressure is a major risk factor for this condition, and controlling it is critical to prevent recurrence.
The study was a randomized, double-blind, placebo-controlled trial, meaning neither the patients nor the doctors knew who was getting the real treatment or a dummy pill. This design is considered the gold standard for testing treatments. The trial included 1,670 patients from multiple countries who had a previous ICH and whose systolic blood pressure (the top number) was between 130 and 160 mm Hg at the start. They were all clinically stable. Half received a once-daily "triple pill" containing 20 mg telmisartan, 2.5 mg amlodipine, and 1.25 mg indapamide, while the other half received a matching placebo. Both groups continued their usual care. The study lasted a median of 2.5 years.
The results were promising. In the triple-pill group, 38 patients (4.6%) had a recurrent stroke, compared to 62 patients (7.4%) in the placebo group. This translates to a 39% lower risk of recurrent stroke (hazard ratio 0.61, 95% CI 0.41 to 0.92, P=0.02). Blood pressure control was also better: the average systolic pressure was 127 mm Hg in the triple-pill group versus 138 mm Hg in the placebo group. Major cardiovascular events (like heart attacks or stroke-related deaths) were also lower: 6.6% versus 9.8% (P=0.04).
Safety was generally acceptable. Serious adverse events occurred in 23.2% of the triple-pill group and 26.0% of the placebo group, suggesting no major safety signal. However, more people in the triple-pill group stopped treatment early due to side effects (13.6% vs. 6.0%). The most common side effect leading to discontinuation was a rise in creatinine levels (a sign of kidney stress). This means that while the triple pill was effective, some patients may not tolerate it well.
It's important to note that this study was presented as an abstract, meaning it has not yet been published in a peer-reviewed journal. The results should be considered preliminary until full publication. Also, the study was funded by government agencies, not drug companies, which reduces potential bias. The researchers used the phrase "associated with" rather than "caused," but the randomized, double-blind design supports a causal link.
For patients who have had a brain bleed, this study offers hope that a simple, once-daily pill combining three low-dose blood pressure medications could help prevent another stroke. However, it's not yet clear if this approach is better than taking the medications separately or using other combinations. Patients should not change their medications based on this single study. Anyone with a history of ICH should discuss their blood pressure goals and treatment options with their doctor. The triple pill is not yet widely available, and more research is needed to confirm these findings and determine long-term safety.